Advertisement
U.S. Markets close in 4 hrs 51 mins

Ocular Therapeutix, Inc. (0OT.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
10.28+0.06 (+0.64%)
As of 03:57PM CEST. Market open.
Full screen
Previous Close10.22
Open10.95
Bid10.40 x 140000
Ask10.73 x 140000
Day's Range10.28 - 10.95
52 Week Range1.88 - 10.95
Volume530
Avg. Volume99
Market Cap1.642B
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-1.01
Earnings DateNov 05, 2024 - Nov 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.43
  • GlobeNewswire

    Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

    SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Pha

  • Zacks

    Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

    Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.